Status:

Lead Sponsor:

No Sponsor

Collaborating Sponsors:

No Collaborator

Conditions:

No Condition

Eligibility:

All genders

Above 18+

Phase:

1/4

Participant Compensation:

n/a

Eligibility Criteria

Inclusion

    Exclusion

      Key Trial Info

      Start Date :

      Trial Type :

      Clinical Trial

      End Date :

      Estimated Enrollment :

      Patients enrolled

      Trial Details

      Trial ID

      Active Locations (0)

      Enter a location and click search to find clinical trials sorted by distance.

      Page 1 of 0 (0 locations)

      No Results Found

      We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

      Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | DecenTrialz